Core Insights - The company reported a revenue of 331 million yuan and a net profit of 63.46 million yuan for the first three quarters of 2025, with a quarterly revenue of 112 million yuan and a net profit of 17.88 million yuan in Q3 [1] - The company is accelerating product commercialization and expanding its global market presence, with its product Olaparib tablets expected to be selected in the recent national centralized drug procurement [1] - The company received FDA approval for its product Tocilizumab sustained-release tablets in October, marking a significant milestone in its product portfolio [1] Product Development - The company made breakthroughs in the diabetes sector, with the approval of new specifications for Sitagliptin Metformin sustained-release tablets by the National Medical Products Administration in September [2] - The product Sitagliptin Metformin sustained-release tablets also received temporary approval from the FDA in October, enhancing the company's international presence in diabetes treatment [2] - The company has established a solid foundation for entering the U.S. market with two products receiving temporary FDA approval in the first half of the year [2] High-end Generic Drugs - The company follows a "first generic, high activity" strategy, achieving global first-generic breakthroughs for several products, including Posaconazole enteric-coated tablets and Macitentan tablets [3] - The company has also received approvals for high-activity formulations such as Olaparib tablets and Exemestane tablets, establishing market barriers [3] - The company's self-developed modified new drug project XT-0043 has shown excellent safety and efficacy in Phase II clinical trials [3] Future Outlook - The company plans to continue driving innovation and steadily advancing its international layout strategy, focusing on enhancing its high-end generic and modified new drug pipeline [3] - The company aims to improve its production quality system and service capabilities while strengthening international cooperation to commercialize more products globally [3]

Core Viewpoint - The company, Shanghai Xuantai Pharmaceutical Co., Ltd., has reported significant developments in its product approvals and market strategies, which are expected to enhance its competitive position and market share in both domestic and international markets [7][9]. Financial Data - The financial statements for the third quarter are unaudited, and the report period covers three months from the beginning to the end of the quarter [3][9]. - The company has not reported any non-recurring gains or losses that are significant enough to be classified differently from regular financial metrics [4][9]. Shareholder Information - As of the end of the reporting period, the company holds 4,336,109 shares in its repurchase account, representing 0.96% of the total share capital [5]. Product Approvals and Market Expansion - The company received approval from the National Medical Products Administration (NMPA) for a new specification of its product, Sitagliptin Metformin Sustained-Release Tablets 50/500mg, which is expected to better meet patient needs and enhance market competitiveness [7]. - The product, Tocilizumab Sustained-Release Tablets 11mg, has received formal approval from the U.S. Food and Drug Administration (FDA), while Sitagliptin Metformin Sustained-Release Tablets have received temporary approval from the FDA, indicating potential for expanded sales in the U.S. market [7]. - The company’s product, Olaparib Tablets, is set to be included in the 11th batch of national centralized drug procurement, which could lead to increased sales and market share if procurement contracts are signed and executed [7].

Core Viewpoint - The company has demonstrated significant progress in its high-end generic drug and CRO/CMO businesses, achieving substantial revenue growth and regulatory approvals for key products in both domestic and international markets [1][2][3] Financial Performance - For the first three quarters of 2025, the company reported a revenue of 331 million yuan and a net profit attributable to shareholders of 63.46 million yuan [1] - In Q3 2025, the company achieved a revenue of 112 million yuan and a net profit of 17.88 million yuan [1] - R&D expenses reached 17.19 million yuan in Q3, accounting for 15.36% of total revenue, reflecting the company's commitment to innovation [2] Product Development and Approvals - The company received approval for new specifications of its Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration in September 2025, enhancing its product matrix in the diabetes sector [1] - In October 2025, the same product received tentative approval from the FDA, marking a significant milestone in the company's internationalization efforts [1] - The company’s Tofacitinib Citrate Extended-Release Tablets 11mg specification received formal approval from the FDA in October [2] - The company’s Olaparib Tablets are expected to be selected in the recent national drug centralized procurement, which will help expand sales and market share [2] R&D and Innovation Strategy - The company focuses on a "first-to-market" strategy in high-end generics, achieving multiple first-generic breakthroughs globally [2] - The company has developed three proprietary R&D technology platforms: "Poorly Soluble Drug Solubilization Technology," "Controlled Release Drug Formulation R&D Platform," and "Fixed-Dose Combination Formulation R&D Platform" [2] - The first self-developed modified new drug project, XT-0043, has shown excellent safety and efficacy in Phase II clinical trials [2] CRO/CMO Business Development - The company leverages its dual-platform in China and the U.S. and multiple GMP certifications to deepen collaborations with domestic and international innovative drug companies [3] - The company has advanced over 100 innovative drug formulation development projects and has established a stable CMO production service model for several successfully launched innovative drugs [3] Future Outlook - The company plans to continue its innovation-driven strategy and steadily advance its international layout, focusing on enhancing its high-end generic and modified new drug pipelines [3] - The controlling shareholder has committed not to reduce its stake in the company for two years starting from August 25, 2025, reflecting confidence in the company's long-term development [3]

Core Insights - The company reported a revenue of 331 million yuan and a net profit of 63.46 million yuan for the first nine months of 2025, with a quarterly revenue of 112 million yuan and a net profit of 17.88 million yuan in Q3 [1] Group 1: Product Development and Market Expansion - The company achieved significant progress in its internationalization strategy, with the FDA approving its 11 mg formulation of tofacitinib citrate in October [1] - The diabetes pipeline saw breakthroughs, with the approval of a new specification for sitagliptin and metformin extended-release tablets by the National Medical Products Administration (NMPA) in September, enhancing the product matrix [2] - The company’s products are now available in multiple countries, including China, the USA, Australia, Canada, and Southeast Asia, creating a diversified global sales structure [2] Group 2: Regulatory Approvals and Quality Certifications - The company’s solid dosage form workshop received GMP certification from the European Medicines Agency (EMA) in July, maintaining a "zero-defect" record in inspections by major global regulatory agencies [3] - The company was awarded the highest information disclosure rating of "A" by the Shanghai Stock Exchange for the 2024-2025 information disclosure evaluation, reflecting its commitment to investor relations and transparency [3] Group 3: Strategic Commitments - The controlling shareholder, Shanghai Lianhe Investment Co., Ltd., voluntarily committed not to reduce its shareholding for two years starting from August 25, 2025, indicating confidence in the company's long-term development strategy [3]

Core Insights - Xuantai Pharmaceutical (688247.SH) reported a revenue of 331 million yuan for the first three quarters of 2025, representing a year-on-year decline of 8.59% [1] - The company's net profit attributable to shareholders was 63.46 million yuan, down 31.45% year-on-year [1] - The non-recurring net profit was 53.88 million yuan, reflecting a year-on-year decrease of 36.64% [1] - Basic earnings per share stood at 0.14 yuan [1]

Group 1 - The core viewpoint of the article highlights the financial performance of Xuantai Pharmaceutical in Q3 2023, indicating a decline in revenue and net profit compared to the previous year [1] - For the first three quarters of 2025, the company's revenue was approximately 331 million yuan, representing a year-on-year decrease of 8.59% [1] - The net profit attributable to shareholders was about 63.46 million yuan, showing a year-on-year decline of 31.45% [1] - The basic earnings per share were reported at 0.14 yuan, which is a decrease of 33.33% year-on-year [1] Group 2 - As of the report date, Xuantai Pharmaceutical's market capitalization stood at 4.9 billion yuan [2]

上海宣泰医药科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 111,857,737.01 | -22.65 | 331,464,771.67 | -8.59 | | 利润总额 | 18,271,847.20 | - ...

宣泰医药公告，第三季度营收为1.12亿元，同比下降22.65%；净利润为1787.68万元，同比下降 53.47%。前三季度营收为3.31亿元，同比下降8.59%；净利润为6346.25万元，同比下降31.45%。 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-046 上海宣泰医药科技股份有限公司自愿披露 关于公司产品拟中选国家药品集中采购的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 10 月 30 日 拟中选产 品名称 适应症 规格包装 拟中选价 格 供应省份 采购周期 奥拉帕利 片 上 皮 性 卵 巢癌、输卵 管 癌 或 原 发 性 腹 膜 癌 150mg*56 片/盒 188.7 元/盒 广 东 、 安 徽、天津、 甘肃、贵州 自 中 选 结 果 执 行 之 日 起 至 2028 年 12 月 31 日 一、拟中选药品基本情况 的影响。 三、风险提示 公司拟中选产品的采购合同签订等后续事项以及带量采购后市场销售执行 情况尚具有不确定性。公司将密切关注该事项的进展情况并及时履行信息披露义 务，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 上海宣泰医药科技股份有限公司董事会 近日，上海宣泰医药科技股份有限公司（以下简称"公司"）参与了国家组 织药品联合采购办公室（以下简称"联采办" ...

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with its product Olaparib tablets expected to be selected in this procurement process [1] Group 1 - The company announced its involvement in the national centralized procurement bidding [1] - The procurement results were published on October 28, 2025, indicating the potential selection of Olaparib tablets [1] - The procurement document number for this process is GY-YD2025-1 [1]